Conjunctivitis as a common adverse effect of dupilumab
in atopic dermatitis

Mikołaj Cichoń; Jowita Sroka-Tomaszewska; Magdalena Trzeciak

doi:10.5114/dr.2022.125683

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

5/2022
vol. 109

Send email

Copy url:

abstract:

Review article

Conjunctivitis as a common adverse effect of dupilumab in atopic dermatitis

Mikołaj Cichoń

¹

,

Jowita Sroka-Tomaszewska

¹

,

Magdalena Trzeciak

¹

Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Gdansk, Poland Katedra i Klinika Dermatologii, Wenerologii i Alergologii, Gdański Uniwersytet Medyczny, Gdańsk, Polska

Dermatol Rev/Przegl Dermatol Rev 2022, 109, 344–351

DOI: https://doi.org/10.5114/dr.2022.125683

Online publish date: 2023/03/16

View full text Get citation

PlumX metrics:

Dupilumab is a monoclonal antibody against the a subunit of the receptor for interleukin 4 and interleukin 13. It is the first biological drug registered in the world for the treatment of atopic dermatitis. Dupilumab turned out to be a milestone in the treatment of atopic dermatitis and an alternative to standard immunosuppressive drugs. In numerous multicenter studies, including real-life studies, it has been proven that dupilumab brings a significant improvement in subjective and objective clinical symptoms in atopic dermatitis. Conjunctivitis is one of the side effects of dupilumab treatment. It is estimated that it affects about 14% of patients with atopic dermatitis. The mechanisms leading to it are not yet fully understood.

keywords:

Conjunctivitis as a common adverse effect of dupilumab in atopic dermatitis

Mikołaj Cichoń 1 , Jowita Sroka-Tomaszewska 1 , Magdalena Trzeciak 1

atopic dermatitis, dupilumab, conjunctivitis

Mikołaj Cichoń

¹

,

Jowita Sroka-Tomaszewska

¹

,

Magdalena Trzeciak

¹